AIRNA is developing RNA editing therapies to treat rare and common diseases by precisely modifying RNA sequences to correct genetic mutations. This approach aims to enhance patient health outcomes by targeting the underlying causes of genetic disorders.
Funding
$120M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+1Founders
Product
Problem
Many diseases, both rare and common, are caused by genetic mutations that lead to the production of dysfunctional proteins or the absence of necessary proteins. Traditional therapeutic approaches often address the symptoms of these diseases without correcting the underlying genetic cause.
Solution
AIRNA is developing a platform for RNA editing therapies designed to precisely correct disease-causing mutations at the RNA level. By modifying RNA sequences, AIRNA's approach aims to restore normal protein function and address the root cause of genetic disorders. This technology has the potential to treat a wide range of diseases by correcting errors in the RNA blueprint before it is translated into protein. The goal is to improve patient outcomes by targeting the fundamental genetic mechanisms driving disease.
Target Audience
The primary target audience includes patients suffering from rare and common diseases caused by genetic mutations, as well as healthcare providers seeking innovative therapies that address the root cause of these conditions.
Features
- RNA editing platform for precise modification of RNA sequences
- Therapeutic approach targets the underlying genetic causes of disease
- Potential to treat both rare and common genetic disorders
- Aims to restore normal protein function by correcting RNA mutations